LAMININS AND NEUROMUSCULAR SYNAPSE FORMATION
层粘连蛋白和神经肌肉突触的形成
基本信息
- 批准号:6499467
- 负责人:
- 金额:$ 30.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-02-09 至 2005-01-31
- 项目状态:已结题
- 来源:
- 关键词:Schwann cells antibody axon biological signal transduction cell differentiation cell growth regulation dendrites electron microscopy gene targeting genetically modified animals immunocytochemistry immunoprecipitation laboratory mouse laminin mixed tissue /cell culture motor neurons mutant neuromuscular junction phenotype protein structure function synaptogenesis
项目摘要
DESCRIPTION (From Applicant's Abstract): Our long-term goal is to understand
the molecular basis of synapse formation in vertebrates. Currently, no
target-derived signals have been firmly established as regulators of nerve
terminal formation in vertebrates. This application focuses on a muscle-derived
cue that controls nerve terminal formation at the neuromuscular junction, the
most-studied synapse. Previous studies identified an activity in the basal
lamina lining the synaptic cleft that induces presynaptic differentiation in
reinnervating axons. The best candidate for mediating that activity is
laminin-11, a muscle-derived component of the synaptic basal lamina. Laminin-11
is a heterotrimer, composed of three homologous laminin "chains": a5, b2, and
g1. Mice lacking laminin-11 through targeted deletion of b2 (s-laminin) die of
neuromuscular failure at one month of age. Motor nerve terminals in the
b2-knock-out are poorly differentiated, and cut axons fail to reinnervate
b2-deficient synaptic sites properly. Purified laminin-11 (but not other
laminins) acts as a "stop" signal to cultured motor neurites, suggesting
laminin-11 directly regulates axons in vivo. Previously, laminin-b2 was thought
to contain the active sites in laminin-11. However, this simple hypothesis is
now insufficient, because another b2-containing laminin (laminin-3, a2b2g1) was
found to promote rather than stop neurite outgrowth. We now hypothesize that
laminin-a5 bears much of the inhibitory activity of laminin-11, and that
presynaptic defects in b2-knock-out mice are largely due to the accompanying
loss of laminin-a5 at b2-deficient synapses. We propose to test this hypothesis
in three ways. We will determine if laminin-a5 is required in vivo for synapse
formation by characterizing laminin a5-knock-out mice. We will determine if
laminin-a5 directly regulates axons, using in vitro assays of neurite outgrowth
on substrates containing purified laminin trimers that contain a5 (but not b2).
Finally, because Schwann cells that surround nerve terminals are also regulated
by laminin-11, we will determine whether laminin-a5 directly regulates nerve
terminal formation by assaying synaptogenesis in nerve-muscle co-cultures,
where Schwann cells can be eliminated. These studies will provide insight into
the mechanisms by which neuronal targets foster and control the pattern of
innervation they receive, and these insights will advance methods of treating
neuromuscular disorders and injuries.
描述(摘自申请人摘要):我们的长期目标是理解
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRUCE L PATTON其他文献
BRUCE L PATTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRUCE L PATTON', 18)}}的其他基金
Matrix Control of Glial/Axonal Interactions in Developing Nerves
神经发育中神经胶质/轴突相互作用的基质控制
- 批准号:
7571086 - 财政年份:2008
- 资助金额:
$ 30.2万 - 项目类别:
相似海外基金
Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
- 批准号:
502607 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
- 批准号:
EP/Y024540/1 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Fellowship
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
- 批准号:
MR/Y008847/1 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
- 批准号:
BB/Y002180/1 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Research Grant
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
- 批准号:
MR/Y003616/1 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
- 批准号:
MR/Y033698/1 - 财政年份:2024
- 资助金额:
$ 30.2万 - 项目类别:
Research Grant
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
- 批准号:
23H03716 - 财政年份:2023
- 资助金额:
$ 30.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis research of anti-Sez6l2 antibody associated encephalopathy
抗Sez6l2抗体相关脑病的分析研究
- 批准号:
23K06940 - 财政年份:2023
- 资助金额:
$ 30.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)